"Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy

J Thorac Oncol. 2016 Oct;11(10):e117-9. doi: 10.1016/j.jtho.2016.05.002. Epub 2016 May 14.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenoma, Pleomorphic / chemically induced
  • Adenoma, Pleomorphic / pathology*
  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Carcinoma / chemically induced
  • Carcinoma / pathology*
  • Disease Progression
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Nivolumab

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab